References
- Fidan C, Aydoğdu A. As a potential treatment of COVID-19: Montelukast. Med Hypotheses. 2020;142:109828. doi:https://doi.org/10.1016/j.mehy.2020.109828.
- Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, Liu L, Shan H, Lei C-L, Hui DSC, China Medical Treatment Expert Group for Covid-19, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi:https://doi.org/10.1056/nejmoa2002032.
- Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629. doi:https://doi.org/10.1172/JCI137244.
- Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest. 2020;130(5):2202–2205. doi:https://doi.org/10.1172/JCI137647.
- Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020;55(4):2000607. doi:https://doi.org/10.1183/13993003.00607-2020.
- Cardani A, Boulton A, Kim TS, Braciale TJ. Alveolar macrophages prevent lethal influenza pneumonia by inhibiting infection of Type-1 alveolar epithelial cells. PLoS Pathog. 2017;13(1):e1006140. doi:https://doi.org/10.1371/journal.ppat.1006140.
- Cingi C, Muluk NB, Ipci K, Şahin E. Antileukotrienes in upper airway inflammatory diseases. Curr Allergy Asthma Rep. 2015;15(11):64. doi:https://doi.org/10.1007/s11882-015-0564-7.
- Mullol J, Callejas FB, Méndez-Arancibia E, Fuentes M, Alobid I, Martinez-Anton A, Valero A, Picado C, Roca-Ferrer J. Montelukast reduces eosinophilic inflammation by inhibiting both epithelial cell cytokine secretion (GM-CSF, IL-6, IL-8) and eosinophil survival. J Biol Regul Homeostatic Agents. 2010;24(4):403–411.
- Davino-Chiovatto JE, Oliveira-Junior MC, MacKenzie B, Santos-Dias A, Almeida-Oliveira AR, Aquino-Junior JCJ, Brito AA, Rigonato-Oliveira NC, Damaceno-Rodrigues NR, Oliveira APL, et al. Montelukast, leukotriene inhibitor, reduces LPS-induced acute lung inflammation and human neutrophil activation. Arch Bronconeumol. 2019;55(11):573–580. doi:https://doi.org/10.1016/j.arbres.2019.05.003.
- CBS New York. Though Not FDA Approved, Off-Label Singulair Showing Promise As Coronavirus Treatment, Say Doctors. 2020. Available from: https://newyork.cbslocal.com/2020/04/22/coronavirus-covid-19-singulair-montelukast/ [last accessed 11 July 2020].
- World Health Organization. COVID-19 Therapeutic Trial Synopsis. 2020. Available from: https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_ Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf [last accessed 16 July 2020].
- Choi J, Azmat CE. Leukotriene Receptor Antagonists. [Updated 2020 Feb 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554445/Kanchanateeraphong.
- Kanchanateeraphong S, Phongsamart G, Dangsuwan T, Vangveeravong M. Study of montelukast for the treatment of acute and post viral-induced wheezing. J Allergy Clin Immunol. 2014;133(2):AB190. doi:https://doi.org/10.1016/j.jaci.2013.12.681.
- Camargo CA, Gurner DM, Smithline HA, Chapela R, Fabbri LM, Green SA, Malice M-P, Legrand C, Dass SB, Knorr BA, et al. A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma. J Allergy Clin Immunol. 2010;125(2):374–380. doi:https://doi.org/10.1016/j.jaci.2009.11.015.
- Straub DA, Moeller A, Minocchieri S, Hamacher J, Sennhauser FH, Hall GL, Wildhaber JH. The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma. Eur Respir J. 2005;25(2):289–294. doi:https://doi.org/10.1183/09031936.05.00031904.
- Johnston SL. Asthma and COVID‐19: is asthma a risk factor for severe outcomes?Allergy. 2020;75(7):1543–1545. doi:https://doi.org/10.1111/all.14348.
- Guan W, Liang W, He J, Zhong N. Cardiovascular comorbidity and its impact on patients with COVID-19. Eur Respir J. 2020;55(6):2001227. doi:https://doi.org/10.1183/13993003.01227-2020.
- Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034. doi:https://doi.org/10.1016/S0140-6736(20)30628-0.
- Maeba S, Ichiyama T, Ueno Y, Makata H, Matsubara T, Furukawa S. Effect of montelukast on nuclear factor κB activation and proinflammatory molecules. Ann Allergy Asthma Immunol. 2005;94(6):670–674. doi:https://doi.org/10.1016/S1081-1206(10)61326-9.
- Reiss TF, Sorkness CA, Stricker W, Botto A, Busse WW, Kundu S, Zhang J. Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax. 1997;52(1):45–48. doi:https://doi.org/10.1136/thx.52.1.45.
- Bozek A, Winterstein J. Montelukast’s ability to fight COVID-19 infection. J Asthma. 2020. doi:https://doi.org/10.1080/02770903.2020.1786112.
- Almerie MQ, Kerrigan DD. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast. Med Hypotheses. 2020;143:109883. doi:https://doi.org/10.1016/j.mehy.2020.109883.